知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

831 records (took 0.048 seconds)

    Peptides selectively lethal to malignant and transformed mammalian cells
    83.
    发明授权
    Peptides selectively lethal to malignant and transformed mammalian cells 有权
    对恶性和转化的哺乳动物细胞选择性致死的肽

    公开(公告)号：US07745405B2

    公开(公告)日：2010-06-29

    申请号：US11977521

    申请日：2007-10-25

    Applicant: Matthew R. Pincus

    Inventor： Matthew R. Pincus

    IPC: A61K38/00 ,  C07K5/00

    CPC classification number: C07K14/4746 ,  A61K38/04 ,  A61K38/10 ,  A61K38/1709 ,  A61K2039/5254 ,  A61K2039/5256 ,  C07K2319/03 ,  C12N2799/022

    Abstract: The present invention provides peptides corresponding to all or a portion of amino acid residues 12-26 of human p53 protein. When fused to a membrane-penetrating leader sequence, the peptides are either lethal to malignant or transformed cells or else cause reversion to the untransformed morphological phenotype. The subject peptides are thus useful in treating neoplastic disease in an animal, preferably a human. Also provided are pharmaceutical compositions comprising the subject peptides admixed with a pharmaceutical acceptable carrier. Methods of treating neoplastic disease in a patient by administering a subject peptide are also provided.

    Abstract translation: 本发明提供对应于人p53蛋白的全部或部分氨基酸残基12-26的肽。 当与膜穿透前导序列融合时，肽对恶性或转化细胞致死，或者导致未转化的形态表型的逆转。 因此，本发明的肽可用于治疗动物，优选人类的肿瘤性疾病。 还提供了包含与药学上可接受的载体混合的受试肽的药物组合物。 还提供了通过施用受试肽治疗患者的肿瘤性疾病的方法。

    High-potency botulinum toxin formulations
    84.
    发明授权
    High-potency botulinum toxin formulations 有权

    公开(公告)号：US07691394B2

    公开(公告)日：2010-04-06

    申请号：US11111951

    申请日：2005-04-22

    Applicant: Gary E. Borodic

    Inventor： Gary E. Borodic

    IPC: A61K38/38

    CPC classification number: C07K14/33 ,  A61K9/0019 ,  A61K38/04 ,  A61K38/4893 ,  A61K47/42

    Abstract: The present invention provides improved formulations of botulinum toxin that increase delivery of the botulinum toxin to neural and associated tissues and exhibit a higher specific neurotoxicity and higher potency (in LD50 Units) than available formulations of botulinum toxins. These improved formulations enable physicians to treat a wide variety of pathological conditions with a lower toxin load that reduces the risk of inducing an immune response against the toxin and its associated proteins that may ultimately lead to the development of toxin resistance. These benefits are particularly important in the treatment of conditions that require high-dose or chronic administration of botulinum toxin. Additionally, the decreased in LD50 Unit doses of inventive formulations allows for controlled administration limits diffusion. The present invention also provides methods of treating neuromuscular diseases and pain, using low-dose botulinum toxin.

    Ketoamide inhibitors in chronic nerve disease
    87.
    发明授权
    Ketoamide inhibitors in chronic nerve disease 失效
    酮酰胺抑制剂在慢性神经疾病中的应用

    公开(公告)号：US07429560B2

    公开(公告)日：2008-09-30

    申请号：US10671360

    申请日：2003-09-25

    Applicant: James C. Powers ,  Jonathan D. Glass

    Inventor： James C. Powers ,  Jonathan D. Glass

    IPC: A61K38/05

    CPC classification number: A61K45/06 ,  A61K38/04 ,  A61K2300/00

    Abstract: Compositions and methods for treating neural pathologies are provided. In particular, compositions and methods for treating neural pathologies including axonal degeneration are provided. The compositions include peptide α-ketomides optionally in combination with a second therapeutic agent. Another aspect of the invention provides compositions and methods for treating hyperproliferative disorders. Exemplary compositions for treating hyperproliferative disorders include an anti-proliferative agent such as paclitaxel, in combination with a calpain inhibitor such as AK295.

    Abstract translation: 提供了治疗神经病变的组合物和方法。 特别地，提供了用于治疗包括轴索变性的神经病变的组合物和方法。 组合物包括任选与第二治疗剂组合的肽α-酮基转移酶。 本发明的另一方面提供了用于治疗过度增殖性疾病的组合物和方法。 用于治疗过度增殖性疾病的示例性组合物包括与钙蛋白酶抑制剂如AK295组合的抗增殖剂如紫杉醇。

    Plant Extracts for the Treatment of Incresed Bone Resorption
    88.
    发明申请
    Plant Extracts for the Treatment of Incresed Bone Resorption 审中-公开
    植物提取物治疗骨折吸收

    公开(公告)号：US20080194492A1

    公开(公告)日：2008-08-14

    申请号：US10580186

    申请日：2004-11-25

    Applicant: Rudolf Brenneisen ,  Roman Conrad Muhlbauer ,  Herbert Wetli

    Inventor： Rudolf Brenneisen ,  Roman Conrad Muhlbauer ,  Herbert Wetli

    IPC: A61K38/05 ,  A61K31/197 ,  A61P3/02 ,  A61K38/16 ,  A61K33/06

    CPC classification number: A61K38/04 ,  A61K38/05

    Abstract: The present invention concerns the use of γ-glutamyl-peptide, for example γ-L-glutamyltrans-S-1-propenyl-L-cysteine sulfoxide, in the treatment or prevention of diseases or conditions which are characterized by increased bone resorption, such as Paget's disease, tumor-induced bone disease or osteoporosis, inhibits dose-dependently the resorption activity of osteoclasts, the minimal effective dose being about 2 mM.

    Abstract translation: 本发明涉及γ-谷氨酰肽，例如γ-L-谷氨酰基反式-S-1-丙烯基-L-半胱氨酸亚砜在治疗或预防以吸收骨吸收增加为特征的疾病或病症中的用途，例如 作为佩吉特病，肿瘤诱导的骨病或骨质疏松症，其剂量依赖性地抑制破骨细胞的吸收活性，最小有效剂量约为2mM。

    Methods for Treating Amyotrophic Lateral Sclerosis
    89.
    发明申请
    Methods for Treating Amyotrophic Lateral Sclerosis 审中-公开
    治疗肌萎缩性侧索硬化症的方法

    公开(公告)号：US20080187490A1

    公开(公告)日：2008-08-07

    申请号：US11470566

    申请日：2006-09-06

    Applicant: Neil M. Bodie ,  Renee Bodie ,  Elliot Altman

    Inventor： Neil M. Bodie ,  Renee Bodie ,  Elliot Altman

    IPC: A61K49/00 ,  A61K38/03 ,  C07K7/06 ,  C07K7/08

    CPC classification number: A61K38/10 ,  A61K38/04 ,  G16B20/00

    Abstract: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, immune complexed IgG binding to IgG FγR, and immune complexed IgG binding to mC1q (membrane C1q) or soluble C1q. The polypeptides and compounds provided herein can have therapeutic use in treating amyotrophic lateral sclerosis (ALS).

    Abstract translation: 可以特异性结合免疫球蛋白分子的C 2 H 3 H 3裂点的多肽和其它化合物，以及使用这些多肽和化合物抑制Fc介导的方法 免疫复合物形成，免疫复合IgG结合IgG FgammaR和免疫复合IgG结合到mC1q（膜C1q）或可溶性C1q。 本文提供的多肽和化合物可用于治疗肌萎缩性侧索硬化症（ALS）的治疗用途。

    Sustained-Release Composition, Process for Producing the Same and Use of the Same
    90.
    发明申请
    Sustained-Release Composition, Process for Producing the Same and Use of the Same 审中-公开
    持续释放组合物，其制备方法和使用方法

    公开(公告)号：US20080118545A1

    公开(公告)日：2008-05-22

    申请号：US11631094

    申请日：2005-06-30

    Applicant: Tomomichi Futo ,  Kei Mukai ,  Jiichi Arai

    Inventor： Tomomichi Futo ,  Kei Mukai ,  Jiichi Arai

    IPC: A61F2/02 ,  A61K38/08

    CPC classification number: A61K38/04 ,  A61K9/0002 ,  A61K9/0019 ,  A61K9/1647 ,  A61K9/5031

    Abstract: A sustained-release composition which comprises (i) a physiologically active substance and (ii) a lactic acid-glycolic acid copolymer in which the weight-average molecular weight (Mw) is about 8,000 to about 11,500, the ratio of the weight-average molecular weight (Mw) to the number-average molecular weight (Mn) is greater than 1.9, and the compositional molar ratio of lactic acid to glycolic acid is 99.9/0.1 to 60/40, or a salt thereof, and which does not contain a drug retaining substance is provided and said sustained-release composition has improved spherical property and/or needle penetrating property.

    Abstract translation: 一种持续释放组合物，其包含（i）生理活性物质和（ii）其中重均分子量（Mw）为约8,000至约11,500的重均分子量（Mw）的乳酸 - 乙醇酸共聚物， 分子量（Mw）与数均分子量（Mn）之比大于1.9，乳酸与乙醇酸的组成摩尔比为99.9 / 0.1〜60/40，或其盐，不含 提供药物保留物质，所述持续释放组合物具有改善的球形性和/或针穿透性。

Patent Agency Ranking